Sanofi India Ltd - 500674 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Girish TekchandaniDesignation :- Company Secretary and Compliance Officer Sanofi India Ltd - 500674 - Shareholding for the Period Ended March 31, 2020
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here
Coronavirus pandemic | Sanofi, GSK come together to develop vaccine for COVID-19
As per the partnership, France-based Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. Sanofi India Ltd - 500674 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The details of securities dematerialized during the quarter ended 31st March 2020, has been submitted by Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company to the stock exchanges where the shares of the Company are listed as per the requirements prescribed under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. A certificate confirming the said compliance received from our RTA is enclosed for your reference. Request you to take the above information on record. Sanofi will donate 100 million doses of hydroxychloroquine to 50 countries
In a statement, the company said it increased its production capacity by 50% across its eight hydroxychloroquine manufacturing sites worldwide, adding it was on track to quadruple it by the summer. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Cessation
Mr. Rangaswamy R. Iyer was appointed as an Independent Director of the Company to hold office for a term of five years from 31st March 2015 to 30th March 2020. On completion of this term, Mr. Iyer ceased to be an Independent Director of the Company at the end of the day on 30th March 2020. Please take the above information on record. Sanofi India Ltd - 500674 - Change In Date For Closing Of Transaction Relating To Slump Sale And Transfer Of The Manufacturing Facility Of The Company At Ankleshwar, Gujarat.
This has reference to our letter dated 11th September 2019 wherein we intimated you that the Board of Directors of Sanofi India Limited (the Company) at its meeting held on 10th September 2019, approved a transaction for the slump sale and transfer of the manufacturing facility at Ankleshwar, Gujarat to Zentiva Private Limited. It was anticipated that the closing of this transaction will be achieved on or before 31st March 2020 and accordingly expected closing dates were announced in disclosures to stock exchanges and postal ballot notice to the shareholders. The shareholders of the Company approved this transaction by way of postal ballot on 30th October 2019. We would like to intimate you that due to delay in receiving regulatory approvals, the closing of this transaction is not likely to be achieved by 31st March 2020. It is now expected that the closing of this transaction will be achieved during the quarter ending 30th June 2020. Sanofi India Ltd - 500674 - Change In Annual General Meeting (AGM) Date & Book Closure Date
The Board of Directors of the Company has taken the following decisions on 23rd March 2020: 1. Postponing the AGM of the Company, which was scheduled on Tuesday, 28th April 2020. A new date will be announced in due course. 2. Cancelling the closure of Register of Members and Share Transfer Books, which was scheduled from 21st April 2020 to 28th April 2020 (both days inclusive) for determining the eligibility of shareholders for payment of final as well as one-time special dividend and Annual General Meeting. The new book closure dates will be announced in due course. 3. The dividend as well as one-time special dividend, if approved by the shareholders, will be paid after the new date of the AGM. Please note that the dividend and one-time special dividend amounts as recommended by the Board of Directors on 25th February 2020 and announced in our letter dated 25th February 2020 will remain unchanged. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.